

VCAM-1, Human CellExp™, Human Recombinant

CATALOG #: 7211-10 10 µg
7211-50 50 µg

ALTERNATE NAMES: CD106, INCAM-100, MGC108734, MGC99561, VCAM, VCAM1, VCAM1B, VECAM1

SOURCE: HEK 293 cells

PURITY: ≥ 98% by SDS-PAGE gel and HPLC analyses

MOL. WEIGHT: ~74.0 kDa

ENDOTOXIN LEVEL: < 0.1 ng/µg of protein (<1 EU/µg).

FORM: Lyophilized

FORMULATION: Sterile filtered through a 0.2 micron filter. Lyophilized from 10 mM Sodium Phosphate, pH 7.0.

STORAGE CONDITIONS: Store at -20°C. After reconstitution, aliquot and store at -20°C to -80°C. Avoid repeated freezing and thawing cycles.

RECONSTITUTION: Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

DESCRIPTION: VCAM is a 110 kDa cell surface integral membrane glycoprotein that belongs to the Ig-related superfamily of adhesion molecules. The primary function of VCAM-1 is the mediation of leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 may play a vital role in the development several diseases, including atherosclerosis and rheumatoid arthritis. The human VCAM-1 gene codes for a 715 amino acid

transmembrane glycoprotein containing a 19 amino acid cytoplasmic domain, a 22 amino acid transmembrane domain, and a 674 amino acid extracellular domain. Recombinant human VCAM-1 is a 74.0 kDa glycoprotein comprising the extracellular domain (673 amino acid residues) of VCAM-1. Monomeric glycosylated VCAM-1 migrates at an apparent molecular weight of approximately 90.0 kDa by SDS-PAGE analysis.

AMINO ACID SEQUENCE:

```
FKIETTPESR YLAQIGDSVS LTCSTTGCEs PFFSWRTQID SPLNGKVTNE
GTTSTLTMNP VSGNEHSYL CTATCESRKL EKGIQVEIYS FPKDPEIHLS
GPLEAGKPIT VKCSVADVYP FDRLEIDLLK GDHLMKSQEF LEDADRKSLE
TKSLEVTFTP VIEDIGKVLV CRAKLHIDEM DSVPTVRQAV KELQVYISPK NTVISVNPST
KLQEGGSVTM TCSSEGLPAP EIFWSKKLDN GNLQHLSGNA TLTLIAMRME
DSGIYVCEGV NLIKGNRKEV ELIVQEKPFT VEISPGPRIA AQIGDSVMLT
CSVMGCESPS FSWRTQIDSP LSGKVRSEGT NSTLTLSPVS FENEHSYLCT
VTCGHKKLEK GIQVELYSFP RDPEIEMSGG LVNGSSVTVS CKVPSVYPLD
RLEIELLKGE TILENIEFLE DTDMSLENK SLEMTFIPTI EDTGKALVCQ AKLHIDDMEF
EPKQRQSTQT LYVNVAPRDT TVLVSPSSIL EEGSSVNMTc LSQGFPPAKI
LWSRQLPNGE LQPLSENATL TLISTKMEDS GVYLCEGINQ AGRSRKEVEL
IIQVTPKDIK LTAFPSESVK EGDTVIISCT CGNVPETWII LKKAETGDT VLKSIDGAYT
IRKAQLKDAG VYECESKNKV GSQLRSLTLD VQGRENKDY FSP
```

BIOLOGICAL ACTIVITY: Determined by its ability to support the adhesion of human U937 cells. The expected ED₅₀ for this effect is 0.8-1.0 µg/ml.

- RELATED PRODUCTS:**
- CD100 Antibody (Clone A8) (Cat. No. 6278-100)
 - CD100 Alexa Fluor® 647 Antibody (Clone A8) (Cat. No. 6279-25)
 - CD100 Alexa Fluor® 488 Antibody (Clone A8) (Cat. No. 6280-25)
 - sCD14, Human Recombinant (Cat. No. 7122-10, -50)
 - sCD22, Human Recombinant (Cat. No. 7123-10, -50)
 - sCD23, Human Recombinant (Cat. No. 7124-10, -50)
 - BLCAM Antibody (Cat. No. 3363-100)
 - HCAM Antibody (Cat. No. 3393-100)
 - CD-14, human recombinant (Cat. No. 4937-100)
 - CD-14, mouse recombinant (Cat. No. 4938-100)
 - CD-14 Antibody (Clone biG 10) (Cat. No. 3676-100)

FOR RESEARCH USE ONLY! Not to be used in humans.

